| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
West China Hospital COVID-19 vaccine is aCOVID-19 vaccine candidate developed byWest China Hospital.[1]
In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.[2]
In November, WestVac Biopharma started phase II clinical trials with 960 participants in China[3] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.[4]
In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.[5]
In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.[6]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
